Evidence map›Paper›PMID 22312136›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2012

Brain and whole-body imaging of nociceptin/orphanin FQ peptide receptor in humans using the PET ligand 11C-NOP-1A.

Talakad G Lohith, Sami S Zoghbi, Cheryl L Morse, Maria F Araneta, Vanessa N Barth, Nancy A Goebl, Johannes T Tauscher, Victor W Pike, Robert B Innis, Masahiro Fujita

Open access · bronzeAbstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016
    Trial
  4. Article
  5. Article
  6. Article
  7. The opioid system in depression.Neuroscience and biobehavioral reviews · 2022
    Review
  8. Anxiety and Depression: What Do We Know of Neuropeptides?Behavioral sciences (Basel, Switzerland) · 2022
    Review
  9. Copper-Mediated Radiocyanation of Unprotected Amino Acids and Peptides.Journal of the American Chemical Society · 2022
    Article
  10. Review
  11. Review
  12. PET Imaging of Phosphodiesterase-4 Identifies Affected Dysplastic Bone in McCune-Albright Syndrome, a Genetic Mosaic Disorder.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020
    Article
  13. Article
  14. Review
  15. A Survey of Molecular Imaging of Opioid Receptors.Molecules (Basel, Switzerland) · 2019
    Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. NOP-Related Mechanisms in Substance Use Disorders.Handbook of experimental pharmacology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Talakad G LohithMolecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892-1026, USA.
Sami S Zoghbi
Cheryl L Morse
Maria F Araneta
Vanessa N Barth
Nancy A Goebl
Johannes T Tauscher
Victor W Pike
Robert B Innis
Masahiro Fujita
National Institute of Mental Health · USEli Lilly (United States) · USNational Institutes of Health · US

Funding

PET Radiopharmaceutical SciencesZIAMH002793 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI PIKE, VICTOR W · 2009 to 2025
$69.8M
Clinical Evaluation of PET RadiotracersZIAMH002852 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI INNIS, ROBERT · 2009 to 2025
$48.6M
Translational Evaluation Of PET RadiotracersZIAMH002795 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI INNIS, ROBERT · 2009 to 2025
$32.0M
Intramural NIH HHS Z99 MH999999
6 · The paper itself

Abstract

unlabelledNociceptin/orphanin FQ peptide (NOP) receptor is a new class of opioid receptor that may play a pathophysiologic role in anxiety and drug abuse and is a potential therapeutic target in these disorders. We previously developed a high-affinity PET ligand, (11)C-NOP-1A, which yielded promising results in monkey brain. Here, we assessed the ability of (11)C-NOP-1A to quantify NOP receptors in human brain and estimated its radiation safety profile.

methodsAfter intravenous injection of (11)C-NOP-1A, 7 healthy subjects underwent brain PET for 2 h and serial sampling of radial arterial blood to measure parent radioligand concentrations. Distribution volume (V(T); a measure of receptor density) was determined by compartmental (1- and 2-tissue) and noncompartmental (Logan analysis and Ichise's bilinear analysis [MA1]) methods. A separate group of 9 healthy subjects underwent whole-body PET to estimate whole-body radiation exposure (effective dose).

resultsAfter (11)C-NOP-1A injection, the peak concentration of radioactivity in brain was high (∼5-7 standardized uptake values), occurred early (∼10 min), and then washed out quickly. The unconstrained 2-tissue-compartment model gave excellent V(T) identifiability (∼1.1% SE) and fitted the data better than a 1-tissue-compartment model. Regional V(T) values (mL·cm(-3)) ranged from 10.1 in temporal cortex to 5.6 in cerebellum. V(T) was well identified in the initial 70 min of imaging and remained stable for the remaining 50 min, suggesting that brain radioactivity was most likely parent radioligand, as supported by the fact that all plasma radiometabolites of (11)C-NOP-1A were less lipophilic than the parent radioligand. Voxel-based MA1 V(T) values correlated well with results from the 2-tissue-compartment model, showing that parametric methods can be used to compare populations. Whole-body scans showed radioactivity in brain and in peripheral organs expressing NOP receptors, such as heart, pancreas, and spleen. (11)C-NOP-1A was significantly metabolized and excreted via the hepatobiliary route. Gallbladder had the highest radiation exposure (21 μSv/MBq), and the effective dose was 4.3 μSv/MBq.

conclusion(11)C-NOP-1A is a promising radioligand that reliably quantifies NOP receptors in human brain. The effective dose in humans is low and similar to that of other (11)C-labeled radioligands, allowing multiple scans in 1 subject.

Indexed as

Bridged Bicyclo Compounds, HeterocyclicRadiopharmaceuticalsSpiro CompoundsAdultBiotransformationBrainFemaleHumansImage Processing, Computer-AssistedIsotope LabelingLinear ModelsMagnetic Resonance ImagingMaleModels, StatisticalNociceptinOpioid Peptides3-(2'-fluoro-6',7'-dihydrospiro(piperidine-4,4'-thieno(3,2-c)pyran)-1-yl)-2-(2-fluorobenzyl)-N-methylpropanamideBridged Bicyclo Compounds, HeterocyclicNociceptinOpioid PeptidesRadiopharmaceuticalsSpiro Compounds

Identifiers

PMID22312136
PMCPMC3835399
OpenAlexW2132911807

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.